NCT00515528 2021-01-26
Vaccination Plus Ontak in Patients With Metastatic Melanoma
University of Chicago
Phase 2 Terminated
Clinical Trials
10 trialsNCT00632827 2020-04-27
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
University of California, San Francisco
Phase 2 Terminated
NCT00425672 2018-12-05
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
University of Washington
Phase 1/2 Completed
NCT01773889 2018-04-10
A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Terminated
NCT00880360 2018-03-27
ONTAK
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT01251952 2017-06-20
Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT00460109 2017-04-18
Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00726037 2016-09-29
A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
Loyola University
Phase 2 Terminated
NCT00337987 2015-02-27
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
Yale University
Phase 2 Completed
NCT00299689 2014-09-05
Phase II Trial of Ontak With Metastatic Melanoma
James Graham Brown Cancer Center
Phase 2 Completed